Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD

Steve W. Turner; Anne B. Chang; Ian A. Yang

doi:10.1183/20734735.0268-2019

Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD

Steve W. Turner, Anne B. Chang, Ian A. Yang

Child and Maternal Health

Research output: Contribution to journal › Review article › peer-review

13 Citations (Scopus)

66 Downloads (Pure)

Abstract

Exhaled nitric oxide fraction (F_ENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. F_ENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect F_ENO, especially atopy, which is associated with elevated F_ENO. One guideline recommends that F_ENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of F_ENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, F_ENO is not recommended for diagnosis or monitoring of COPD. Although F_ENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of F_ENO as an objective measurement in asthma and COPD can be realised.

Original language	English
Pages (from-to)	306-316
Number of pages	11
Journal	Breathe
Volume	15
Issue number	4
DOIs	https://doi.org/10.1183/20734735.0268-2019
Publication status	Published - 1 Dec 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1183/20734735.0268-2019Licence: CC BY-NC

26273218-oaFinal published version, 284 KBLicence: CC BY-NC

Cite this

@article{69ee7dd721f848209ad0c48230c83326,

title = "Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD",

abstract = "Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.",

author = "Turner, {Steve W.} and Chang, {Anne B.} and Yang, {Ian A.}",

year = "2019",

month = dec,

day = "1",

doi = "10.1183/20734735.0268-2019",

language = "English",

volume = "15",

pages = "306--316",

journal = "Breathe",

issn = "1810-6838",

publisher = "European Respiratory Society",

number = "4",

}

TY - JOUR

T1 - Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD

AU - Turner, Steve W.

AU - Chang, Anne B.

AU - Yang, Ian A.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.

AB - Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.

UR - http://www.scopus.com/inward/record.url?scp=85075948552&partnerID=8YFLogxK

U2 - 10.1183/20734735.0268-2019

DO - 10.1183/20734735.0268-2019

M3 - Review article

C2 - 31803265

AN - SCOPUS:85075948552

SN - 1810-6838

VL - 15

SP - 306

EP - 316

JO - Breathe

JF - Breathe

IS - 4

ER -

Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this